UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 109

Sortiert nach

Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis

Oncogene, 2015-05, Vol.34 (19), p.2450-2460

2015

Volltextzugriff (PDF)

Abstract No. 176 Influence of Clinical and Procedural Factors on Rate of Cholecystostomy Tube Dislodgement and Other Complications

Journal of vascular and interventional radiology, 2023-03, Vol.34 (3), p.S80-S81

2023

Volltextzugriff (PDF)

Iconographie du quotidien dans l’art provincial romain : modèles régionaux

Lefebvre, Sabine

2017

Volltextzugriff (PDF)

Autophagy mediates HIF2[alpha] degradation and suppresses renal tumorigenesis

Oncogene, 2015-05, Vol.34 (19), p.2450

2015

Volltextzugriff (PDF)

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

The lancet oncology, 2013-11, Vol.14 (12), p.1233-1242

2013

Volltextzugriff (PDF)

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

Oncogene, 2016-05, Vol.35 (21), p.2687-2697

2016

Volltextzugriff (PDF)

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

Annals of oncology, 2021-05, Vol.32 (5), p.661-672

2021

Volltextzugriff (PDF)

High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma

Oncogene, 2016-03, Vol.35 (12), p.1565-1574

2016

Volltextzugriff (PDF)

Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules

Oncogene, 2014-06, Vol.33 (26), p.3463-3472

2014

Volltextzugriff (PDF)

Noninvasive detection of any-stage cancer using free glycosaminoglycans

Proceedings of the National Academy of Sciences - PNAS, 2022-12, Vol.119 (50), p.e2115328119-e2115328119

2022

Volltextzugriff (PDF)

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay

Annals of oncology, 2022-11, Vol.33 (11), p.1204-1206

2022

Volltextzugriff (PDF)

Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients

Clinical cancer research, 2012-07, Vol.18 (14), p.3961-3971

2012

Volltextzugriff (PDF)

Comprehensivemolecular characterization of clear cell renal cell carcinoma

Nature (London), 2013-07, Vol.499 (7456), p.43

2013

Volltextzugriff (PDF)

Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2018-06, Vol.36 (16), p.1588-1593

2018

Volltextzugriff (PDF)

Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas

Clinical cancer research, 2013-05, Vol.19 (9), p.2460-2472

2013

Volltextzugriff (PDF)

671P Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from the 2020 Global Patient Survey from 41 countries

Annals of oncology, 2021-09, Vol.32, p.S695-S695

2021

Volltextzugriff (PDF)

Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma

Annals of oncology, 2010-08, Vol.21 (8), p.1599-1606

2010

Volltextzugriff (PDF)

Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function

Oncogene, 2016-09, Vol.35 (38), p.4973-4980

2016

Volltextzugriff (PDF)

Pilot trial of sunitinib therapy in patients with von Hippel–Lindau disease

Annals of oncology, 2011-12, Vol.22 (12), p.2661-2666

2011

Volltextzugriff (PDF)

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

Annals of oncology, 2012-01, Vol.23 (1), p.46-52

2012

Volltextzugriff (PDF)

Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al

Annals of oncology, 2021-09, Vol.32 (9), p.1194-1197

2021

Volltextzugriff (PDF)

Abstract SP084: Replication stress response defects predict responses to ICT in non-hypermutated tumors

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.SP084-SP084

2021

Volltextzugriff (PDF)

Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial

The lancet oncology, 2018-10, Vol.19 (10), p.1351-1359

2018

Volltextzugriff (PDF)

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma

Cancers, 2021-04, Vol.13 (9), p.2170

2021

Volltextzugriff (PDF)

Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects

Genome research, 2014-02, Vol.24 (2), p.241

2014

Volltextzugriff (PDF)

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(105)
Mit Volltextzugriff
(99)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(54)
Life Sciences & Biomedicine
(52)
Humans
(48)
Oncology
(34)
Female
(27)
Male
(27)
Middle Aged
(23)
Adult
(19)
Kidney Neoplasms - Pathology
(18)
Carcinoma, Renal Cell - Pathology
(17)
Aged
(15)
Treatment Outcome
(14)
Kidney Cancer
(13)
Renal Cell Carcinoma
(13)
Carcinoma, Renal Cell - Drug Therapy
(12)
Kidney Neoplasms - Drug Therapy
(12)
Mutation
(12)
Tumors
(12)
Biological And Medical Sciences
(11)
Medical Sciences
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(28)
Annals Of Oncology
(17)
Oncogene
(6)
Clinical Cancer Research
(4)
Urologic Oncology
(4)
The Journal Of Urology
(3)
The Lancet Oncology
(3)
American Journal Of Clinical Oncology
(2)
Bju International
(2)
Cancer
(2)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis

Abstract No. 176 Influence of Clinical and Procedural Factors on Rate of Cholecystostomy Tube Dislodgement and Other Complications

Iconographie du quotidien dans l’art provincial romain : modèles régionaux

Autophagy mediates HIF2[alpha] degradation and suppresses renal tumorigenesis

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma

Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules

Noninvasive detection of any-stage cancer using free glycosaminoglycans

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay

Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients

Comprehensivemolecular characterization of clear cell renal cell carcinoma

Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma

Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas

671P Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from the 2020 Global Patient Survey from 41 countries

Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma

Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function

Pilot trial of sunitinib therapy in patients with von Hippel–Lindau disease

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al

Abstract SP084: Replication stress response defects predict responses to ICT in non-hypermutated tumors

Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma

Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects

Suchergebnisse filtern